Alector, Inc. (ALEC)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
1.84 USD
-0.07
(-3.665%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 1.85 +0.01 (0.543%) ⇧ (Oct. 16, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 1:18 a.m. EDT
The investment case for Alector has collapsed due to a catastrophic failure in both its business fundamentals and its strategic partnerships. The company is trapped in a multi-year structural decline, having lost nearly 80% of its value over the last six years while posting five consecutive years of negative annual returns. The recent termination of the GSK neuroscience pact confirms the narrative of a pipeline reset that the market has already priced in as a terminal event for the current strategy. Fundamentally, the picture is dire: revenues are contracting by nearly 58%, operating cash flow is burning at a rate of roughly $158 million annually, and the balance sheet shows negative book value with massive free cash flow outflows. While the cash pile provides a temporary runway, it cannot offset the reality that the core business is shrinking and losing money. The options market reflects this pessimism perfectly, with heavy put buying suggesting traders are betting on further drops rather than a recovery. There is no catalyst here to justify a turnaround story; the data points to a company struggling to survive in a competitive landscape where its key assets are being abandoned by partners. Avoid. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.092431 |
| AutoTheta | 0.092443 |
| MSTL | 0.094044 |
| AutoARIMA | 0.188509 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 0.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.181 |
| Excess Kurtosis | -0.98 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.128 |
| Market Cap | 205,448,736 |
| Forward P/E | -2.51 |
| Beta | 0.62 |
| Website | https://www.alector.com |
As of Oct. 10, 2026, 1:18 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across all expirations, with deep out-of-the-money puts holding the highest concentration of open interest relative to volume. This indicates a market consensus expecting further price weakness, likely driven by the recent corporate partnership termination.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.44410878 |
| Address1 | 131 Oyster Point Boulevard |
| Address2 | Suite 600 |
| All Time High | 43.32 |
| All Time Low | 0.87 |
| Ask | 2.31 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 2.6 - Hold |
| Average Daily Volume10 Day | 12,786,150 |
| Average Daily Volume3 Month | 3,071,092 |
| Average Volume | 3,071,092 |
| Average Volume10Days | 12,786,150 |
| Beta | 0.62 |
| Bid | 1.57 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | -0.089 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.84 |
| Current Ratio | 5.26 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.18 |
| Day Low | 1.795 |
| Display Name | Alector |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,754,598,600 |
| Earnings Call Timestamp Start | 1,754,598,600 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -119,029,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.55 |
| Enterprise To Revenue | 4.718 |
| Enterprise Value | 65,408,732 |
| Eps Current Year | -0.504 |
| Eps Forward | -0.734 |
| Eps Trailing Twelve Months | -1.09 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.0942 |
| Fifty Day Average Change | -0.25419986 |
| Fifty Day Average Change Percent | -0.12138281 |
| Fifty Two Week Change Percent | -44.410877 |
| Fifty Two Week High | 3.335 |
| Fifty Two Week High Change | -1.495 |
| Fifty Two Week High Change Percent | -0.44827586 |
| Fifty Two Week Low | 1.09 |
| Fifty Two Week Low Change | 0.75 |
| Fifty Two Week Low Change Percent | 0.6880734 |
| Fifty Two Week Range | 1.09 - 3.335 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,549,549,800,000 |
| Float Shares | 84,953,050 |
| Forward Eps | -0.734 |
| Forward P E | -2.5068119 |
| Free Cashflow | -107,252,496 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 103 |
| Fullday Change | -0.059999943 |
| Fullday Change Percent | -3.1413584 |
| Fullday Price | 1.84 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -85,267,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0738 |
| Held Percent Institutions | 0.70223 |
| Implied Shares Outstanding | 111,656,919 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California. |
| Long Name | Alector, Inc. |
| Market | us_market |
| Market Cap | 205,448,736 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_249249899 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -117,854,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 224,430,407 |
| Number Of Analyst Opinions | 5 |
| Open | 2.18 |
| Operating Cashflow | -158,232,000 |
| Operating Margins | -7.34729 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 415 231 5660 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.5434777 |
| Post Market Price | 1.85 |
| Post Market Time | 1,792,195,184 |
| Previous Close | 1.91 |
| Price Eps Current Year | -3.6507936 |
| Price Hint | 4 |
| Price To Book | -20.674158 |
| Price To Sales Trailing12 Months | 14.819933 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.047 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.57143 |
| Region | US |
| Regular Market Change | -0.0699999 |
| Regular Market Change Percent | -3.66492 |
| Regular Market Day High | 2.18 |
| Regular Market Day Low | 1.795 |
| Regular Market Day Range | 1.795 - 2.18 |
| Regular Market Open | 2.18 |
| Regular Market Previous Close | 1.91 |
| Regular Market Price | 1.84 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 5,149,923 |
| Return On Assets | -0.27617002 |
| Return On Equity | -3.85112 |
| Revenue Growth | -0.578 |
| Revenue Per Share | 0.128 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 111,656,919 |
| Shares Percent Shares Out | 0.0551 |
| Shares Short | 6,147,032 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,165,227 |
| Short Name | Alector, Inc. |
| Short Percent Of Float | 0.0583 |
| Short Ratio | 4.35 |
| Source Interval | 15 |
| State | CA |
| Symbol | ALEC |
| Target High Price | 8.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 3.9 |
| Target Median Price | 3.0 |
| Total Cash | 172,798,000 |
| Total Cash Per Share | 1.548 |
| Total Debt | 32,758,000 |
| Total Revenue | 13,863,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.09 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.017575 |
| Two Hundred Day Average Change | -0.17757499 |
| Two Hundred Day Average Change Percent | -0.08801407 |
| Type Disp | Equity |
| Volume | 5,149,923 |
| Website | https://www.alector.com |
| Zip | 94,080 |